Loading
A phase 2 trial of Ivonescimab, Carboplatin, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, active and no longer recruiting.
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC is a phase 2 interventional study registered as NCT05247684 by Akeso, with 90 participants enrolled, started 2022-02-20 and due to reach its primary completion in 2025-08-18. Interventions recorded: AK112, Carboplatin, Cisplatin, Paclitaxel. Conditions listed: Resectable Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Akeso, Ivonescimab, Carboplatin, Small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Akeso, Ivonescimab, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Resectable stage I to III non-small-cell lung cancer, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Paclitaxel / nab-paclitaxel, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Akeso, Ivonescimab, Paclitaxel / nab-paclitaxel.
Shares Resectable stage I to III non-small-cell lung cancer, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Resectable stage I to III non-small-cell lung cancer, Cisplatin, Carboplatin, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/